Abstract
Proteasome inhibitors (PIs) and immunomodulatory drugs (IMiDs) have significantly improved survival in Multiple Myeloma (MM) patients, but patients continue to progress or become refractory to these treatments, requiring the use of additional lines of therapy (LOTs). This retrospective study assessed real world healthcare resource utilization (HCRU) and subsequent costs in MM patients in the United States, after receiving 1-3 LOTs, exposed to a PI and an IMiD, and exposed to (and discontinued) lenalidomide.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
